Table 4. Management of Neurologic Toxicity (Excluding ICANS).

Adverse reaction	Severity	Actions
Neurologic toxicity (excluding ICANS)	Grade 1	Withhold teclistamab-cqyv until neurologic toxicity symptoms resolve or stabilize.
	Grade 2 Grade 3 (first occurrence)	Withhold teclistamab-cqyv until neurologic toxicity symptoms improve to grade 1 or less. Provide supportive therapy.
	Grade 3 (recurrent) Grade 4	Permanently discontinue teclistamab-cqyv. Provide supportive therapy, which may include intensive care.

Note. Adverse events grading according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). ICANS = immune effector cell–associated neurotoxicity syndrome. Information from Janssen Biotech, Inc. (2022).